Company Overview and News
2018-09-21 seekingalpha - 2
Huge dividend cuts during 2008-2009 combined with unstable dividend payments are causes for concern for dividend-seeking investors.
VIG WFCNP PM MTSI PG XOM ABT WMT VZA CSCO KO VYM INTC MCD MMM ABT WFC UNP MDT T JNJ CVX VZ MSFT PFE
On Sep 19, we issued an updated research report on Abbott Laboratories (ABT - Free Report) . Notably, branded generics and international diabetes businesses of Abbott should drive growth in the coming quarters. Nevertheless, a competitive environment persists to raise concerns for Abbott. The stock carries a Zacks Rank #3 (Hold).
ABT WFC WFCNP ISRG ABT RHT VEEV ATHN CSIQ
The medical products sector has been gaining prominence on the back of encouraging demographics, changing market dynamics toward Artificial Intelligence (AI), big-data applications and increased business investments.
ABT QDEL SRDX ICUI ABT MEDD
EXTON, Pa., Sept. 18, 2018 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a pharmaceutical company focused on the development and commercialization of its proprietary immune modulator, tilsotolimod, for the treatment of cancer, today announced that Howard Pien joined its Board of Directors, effective September 18, 2018.
ABT SAGE INVVY IDRAW JUNO IDRA VNDA IZQVF ABT
Technological advancements can at times be a bane. Medical devices linked to the cloud and the Internet of Things (IoT) are now quite a double-edged sword. While they effectively enhance the treatment procedure, these devices are exposed to cyber risks.
ABT HMSY FLGT ATHN ABT
On Sep 12, we issued an updated research report on Cardiovascular Systems, Inc. (CSII - Free Report) . Tough competition, consistent operating loss and an anticipated failure to grow business overseas continue to pose threats to this stock. The player carries a Zacks Rank #5 (Strong Sell).
MASI ABT CY CSII AMED ISRG ABT
MITRA-FR results in late August missed primary endpoints and was incrementally negative for MitraClip’s prospects at expanding into the functional mitral valve regurgitation indication.
ABT LIVN BSX MR LIVN ABT EW MDT
Exchange traded funds ("ETFs") that focus on companies that pay dividends, follow a wide variety of stock selection strategies. These range from simply selecting the highest yielding dividend paying stocks in the market to sophisticated proprietary strategies with multiple selection criteria. We analyze the investment results of the most popular U.S. listed ETFs to determine which strategies work.
VIG ABT MTSI UNP O OPRF ABT MCY HRL SDY VALU ABM TRI MSFT
NEW DELHI: The Indian government has banned 328 combination drugs in a blow to both domestic and foreign pharmaceutical firms, but the ban has been cheered by health activists worried about growing antibiotic resistance due to the misuse of medicines.
2018-09-12 investorplace - 1
Once investors retire, the priority usually turns to income. Here, they want their assets to generate as much cash as they can with as little risk. In today’s lending environment, CDs and bonds will probably not produce enough money. They could turn to distributions from mutual funds or exchange-traded-funds that hold some of these retirement stocks. However, with the dividend yield of the S&P 500 holding at about 1.
ABT SNHNI TGT AMZN T CVX SNH ABBV SNHNL WMT
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
2018-09-18 - Asif
Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...
2018-09-18 - Asif
Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...
Silicon Investor Message Boards
This table lists all message boards related to ABT / Abbott Laboratories on message board site Silicon Investor.
as of ET